logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11944625 B1

PDFFull Text
Date of Patent:
Apr. 02, 2024

Filed:

Feb. 12, 2021

Calmodulin inhibitors, chk2 inhibitors and rsk inhibitors for the treatment of ribosomal disorders and ribosomapathies

Applicants:

The Children's Medical Center Corporation, Boston, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

James Bradner, Weston, MA (US);

Jun Qi, Sharon, MA (US);

Dennis Buckley, Cambridge, MA (US);

Leonard I. Zon, Brookline, MA (US);

Elizabeth Macari, Wilmington, MA (US);

Assignees:

THE CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US);

DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);

Attorneys:

NIXON PEABODY LLP

David S. Resnick

Ravinderjit Braich

Primary Examiner:

Theodore R Howell

Assistant Examiner:

George W Kosturko

Int. Cl.
CPC ...
A61K 31/517 (2006.01); A61K 31/225 (2006.01); A61K 31/403 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/5415 (2006.01); A61K 31/55 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61P 7/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 31/225 (2013.01); A61K 31/403 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5415 (2013.01); A61K 31/55 (2013.01); A61K 31/7048 (2013.01); A61P 7/06 (2018.01); A61K 45/06 (2013.01);
Abstract

The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.

Find Patent Forward Citations

Bradner, James. (2024). Calmodulin inhibitors, chk2 inhibitors and rsk inhibitors for the treatment of ribosomal disorders and ribosomapathies (U.S. Patent No. 11944625). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11944625

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…